These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 7634183)

  • 1. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin stimulation after pituitary desensitization with leuprolide acetate, comparison of FSH/hMG and hMG alone cycles--a study of 166 cases.
    Hwang FR; Chang MY; Soong YK
    Changgeng Yi Xue Za Zhi; 1993 Dec; 16(4):223-30. PubMed ID: 8313205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled ovarian hyperstimulation for the new reproductive technologies.
    Navot D; Sandler B
    Acta Eur Fertil; 1989; 20(4):217-21. PubMed ID: 2519574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K; Muasher SJ; Brzyski RG; Jones GS; Simonetti S; Liu HC; Rosenwaks Z
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.
    Edelstein MC; Brzyski RG; Jones GS; Oehninger S; Sieg SM; Muasher SJ
    J In Vitro Fert Embryo Transf; 1990 Jun; 7(3):172-6. PubMed ID: 2116488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program].
    Usui A
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1431-8. PubMed ID: 2511261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.
    Wang PT; Lee RK; Su JT; Hou JW; Lin MH; Hu YM
    J Assist Reprod Genet; 2002 Jan; 19(1):1-6. PubMed ID: 11893009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET).
    Segars JH; Hill GA; Bryan SH; Herbert CM; Osteen KG; Rogers BJ; Wentz AC
    J In Vitro Fert Embryo Transf; 1990 Dec; 7(6):327-31. PubMed ID: 2127603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.